# ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

> **NCT07021989** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Michael Spinner, MD** · enrollment: 38 (estimated)

## Conditions studied

- Hodgkin Lymphoma, Adult
- Refractory Hodgkin Lymphoma
- Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Non-investigational, involved site radiotherapy (ISRT)
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine
- **DRUG:** Liposomal Doxorubicin
- **DEVICE:** Foresight CLARITY™ LDT
- **DRUG:** Pegfilgrastim
- **PROCEDURE:** Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)

## Key facts

- **NCT ID:** NCT07021989
- **Lead sponsor:** Michael Spinner, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-03-31
- **Final completion:** 2033-10-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07021989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07021989, "ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07021989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*